J&J Medical Connect
Neuroscience
Neuroscience

Congress Materials – International Congress on Neuromuscular Diseases (ICNMD 2026)

This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.

AChR-Autoantibody Detection and Therapeutic Assessment of Nipocalimab in Seronegative Patients with Myasthenia Gravis in Vivacity-MG3

Silke Miller, Gallen Triana-Baltzer, Hans Frykman, Anna Mammel, Pankaj Kumar, Marie Fitzgibbon, Michael Kutch, Laura Green, Sindhu Ramchandren, Matteo Gastaldi


This document will be available after July 8th 2026

Assessing Relationship Between IgG-Levels and Infection Rate in Nipocalimab-Treated Patients with Generalized Myasthenia Gravis (Vivacity-MG3)

Ghazala Hayat, Ricardo Rojo Cella, Robert Edwards, Marie Fitzgibbon, Robert Gordon, Wim Noel, Zia Choudhry, Kavita Gandhi, Sindhu Ramchandren, Kevin L. Winthrop, Carlo Antozzi


This document will be available after July 8th 2026

Assessing Relationship Between Immunoglobulin-G Level and Nipocalimab Efficacy using Myasthenia Gravis-Activities of Daily Living Scale

Zabeen Mahuwala, Ruben Faelens, Belen Valenzuela, Martine Neyens, Yaowei Zhu, Jocelyn Leu, Marie Fitzgibbon, Sindhu Ramchandren, Juan-Jose Perez Ruixo


This document will be available after July 8th 2026

Corticosteroid Usage in Patients with Generalized Myasthenia Gravis Receiving Nipocalimab: Phase 3 Vivacity-MG3 Open-Label Extension

Yuebing Li, Kavita Gandhi, Wisam Karmous, Marie Fitzgibbon, Ibrahim Turkoz, I-Ching Tsai, Zia Choudhry, Wim Noel, Louis Jackson, Sindhu Ramchandren, Hiroyuki Murai


This document will be available after July 8th 2026

Effect of Nipocalimab on Sustained Myasthenia Gravis Control During Infections: Post-hoc Analysis of Vivacity-MG3 Study

Carlo Antozzi, Gonçalo M.C. Rodrigues, Marie Fitzgibbon, Robert Edwards, Ibrahim Turkoz, Michael Kutch, Sindhu Ramchandren, Ghazala S. Hayat


This document will be available after July 8th 2026

Efficacy and Safety of Nipocalimab: Switch From 15-mg/kg Every-2-Week to 30-mg/kg Every-4-Week (VIVACITY-MG3 Open-Label Extension)

Tuan Vu, Marie Fitzgibbon, Kavita Gandhi, Nolan Campbell, Yaowei Zhu, Jocelyn Leu, Ibrahim Turkoz, Sindhu Ramchandren


This document will be available after July 8th 2026

Efficacy of Nipocalimab in Patients Early in Their Disease Course of Generalized Myasthenia Gravis

Carlo Antozzi, Wim Noel, Marie Fitzgibbon, Wisam Karmous, Kavita Gandhi, Ibrahim Turkoz, Michael Kutch, Sindhu Ramchandren, Elena Cortés-Vicente


This document will be available after July 8th 2026

Efficacy of Nipocalimab in Patients with Myasthenia Gravis and Lower Baseline Activity of Daily Living

Carlo Antozzi, Wim Noel, Wisam Karmous, Marie Fitzgibbon, Kavita Gandhi, Ibrahim Turkoz, Michael Kutch, Sindhu Ramchandren


This document will be available after July 8th 2026

Long-Term Safety and Efficacy of Nipocalimab: Approximately 2 Years Follow-Up Results From Vivacity-MG3 Open-Label Extension

Carlo Antozzi, Tuan Vu, Sindhu Ramchandren, Richard J. Nowak, Constantine Farmakidis, Vera Bril, Jan De Bleecker, Huan Yang, Eduard Minks, Jin-Sung Park, Mariusz Grudniak, Marek Smilowski, Teresa Sevilla, Sarah Hoffmann, Kumaraswamy Sivakumar, Panna Sanga, Ibrahim Turkoz, Yaowei Zhu, Marie Fitzgibbon, Michel Burcklen


This document will be available after July 8th 2026

 

Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.

Would you like to clear and leave your conversation? Message history will be lost.